PARDES BIOSCIENCES, INC.

Pardes Biosciences, Inc., formerly known as FS Development Corp. II (Nasdaq: FSII), is a clinical-stage antiviral biopharmaceutical company that completed its de-SPAC merger with FS Development Corp. II in early 2022. The blank-check vehicle, which priced its initial public offering in 2021 and was sponsored by FS Development Corp., focused on the healthcare and life sciences sector. The company filed an 8-K with the SEC on August 31, 2023, reflecting a post-merger corporate disclosure. Pardes Biosciences has been engaged in the development of oral antiviral therapeutics targeting respiratory illnesses, operating in a competitive and capital-intensive segment of the biopharmaceutical industry. Visit SpacDesk and sign up for full filing history, sponsor profiles, and real-time SPAC data on FSII and hundreds of other transactions.